264 related articles for article (PubMed ID: 27397576)
1. Incidence of Second Malignancies of Chronic Myeloid Leukemia During Treatment With Tyrosine Kinase Inhibitors.
Yin XF; Wang JH; Li X; Yu MX; Ma ZX; Jin J
Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):577-581. PubMed ID: 27397576
[TBL] [Abstract][Full Text] [Related]
2. Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors.
Nakazato T; Iriyama N; Tokuhira M; Ishikawa M; Sato E; Takaku T; Sugimoto KJ; Fujita H; Fujioka I; Kimura Y; Aisa Y; Iwanaga E; Asou N; Kizaki M; Hatta Y; Komatsu N; Kawaguchi T
Med Oncol; 2018 May; 35(7):99. PubMed ID: 29846829
[TBL] [Abstract][Full Text] [Related]
3. Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era.
Gunnarsson N; Stenke L; Höglund M; Sandin F; Björkholm M; Dreimane A; Lambe M; Markevärn B; Olsson-Strömberg U; Richter J; Wadenvik H; Wallvik J; Själander A
Br J Haematol; 2015 Jun; 169(5):683-8. PubMed ID: 25817799
[TBL] [Abstract][Full Text] [Related]
4. Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia.
Voglova J; Muzik J; Faber E; Zackova D; Klamova H; Steinerova K; Michalovicova Z; Demitrovicova L; Cmunt E; Novakova L; Tothova E; Belohlavkova P; Mayer J; Indrak K
Neoplasma; 2011; 58(3):256-62. PubMed ID: 21395367
[TBL] [Abstract][Full Text] [Related]
5. Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Sasaki K; Kantarjian HM; O'Brien S; Ravandi F; Konopleva M; Borthakur G; Garcia-Manero G; Wierda WG; Daver N; Ferrajoli A; Takahashi K; Jain P; Rios MB; Pierce SA; Jabbour EJ; Cortes JE
Int J Hematol; 2019 May; 109(5):545-552. PubMed ID: 30830579
[TBL] [Abstract][Full Text] [Related]
6. Chronic myeloid leukemia incidence, survival and accessibility of tyrosine kinase inhibitors: a report from population-based Lithuanian haematological disease registry 2000-2013.
Beinortas T; Tavorienė I; Žvirblis T; Gerbutavičius R; Jurgutis M; Griškevičius L
BMC Cancer; 2016 Mar; 16():198. PubMed ID: 26956037
[TBL] [Abstract][Full Text] [Related]
7. Imatinib Intolerance Is Associated With Blastic Phase Development in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia.
Ángeles-Velázquez JL; Hurtado-Monroy R; Vargas-Viveros P; Carrillo-Muñoz S; Candelaria-Hernández M
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S82-5. PubMed ID: 27521331
[TBL] [Abstract][Full Text] [Related]
8. Are chronic myeloid leukemia patients more at risk for second malignancies? A population-based study.
Rebora P; Czene K; Antolini L; Gambacorti Passerini C; Reilly M; Valsecchi MG
Am J Epidemiol; 2010 Nov; 172(9):1028-33. PubMed ID: 20861143
[TBL] [Abstract][Full Text] [Related]
9. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV.
Miranda MB; Lauseker M; Kraus MP; Proetel U; Hanfstein B; Fabarius A; Baerlocher GM; Heim D; Hossfeld DK; Kolb HJ; Krause SW; Nerl C; Brümmendorf TH; Verbeek W; Fauser AA; Prümmer O; Neben K; Hess U; Mahlberg R; Plöger C; Flasshove M; Rendenbach B; Hofmann WK; Müller MC; Pfirrmann M; Hochhaus A; Hasford J; Hehlmann R; Saußele S
Leukemia; 2016 Jun; 30(6):1255-62. PubMed ID: 26859076
[TBL] [Abstract][Full Text] [Related]
10. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
Lang AS; Mounier M; Roques M; Chretien ML; Boulin M
J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674
[TBL] [Abstract][Full Text] [Related]
11. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.
Verma D; Kantarjian H; Strom SS; Rios MB; Jabbour E; Quintas-Cardama A; Verstovsek S; Ravandi F; O'Brien S; Cortes J
Blood; 2011 Oct; 118(16):4353-8. PubMed ID: 21846902
[TBL] [Abstract][Full Text] [Related]
12. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2016 Feb; 91(2):252-65. PubMed ID: 26799612
[TBL] [Abstract][Full Text] [Related]
13. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
[TBL] [Abstract][Full Text] [Related]
14. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
Wong SF; Mirshahidi H
Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
[TBL] [Abstract][Full Text] [Related]
15. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.
Gambacorti-Passerini C; Antolini L; Mahon FX; Guilhot F; Deininger M; Fava C; Nagler A; Della Casa CM; Morra E; Abruzzese E; D'Emilio A; Stagno F; le Coutre P; Hurtado-Monroy R; Santini V; Martino B; Pane F; Piccin A; Giraldo P; Assouline S; Durosinmi MA; Leeksma O; Pogliani EM; Puttini M; Jang E; Reiffers J; Piazza R; Valsecchi MG; Kim DW
J Natl Cancer Inst; 2011 Apr; 103(7):553-61. PubMed ID: 21422402
[TBL] [Abstract][Full Text] [Related]
16. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Rochau U; Sroczynski G; Wolf D; Schmidt S; Jahn B; Kluibenschaedl M; Conrads-Frank A; Stenehjem D; Brixner D; Radich J; Gastl G; Siebert U
Leuk Lymphoma; 2015; 56(8):2315-25. PubMed ID: 25393806
[TBL] [Abstract][Full Text] [Related]
18. Imatinib in the treatment of chronic myeloid leukemia in children and adolescents is effective and well tolerated: Report of the Polish Pediatric Study Group for the Treatment of Leukemias and Lymphomas.
Janeczko-Czarnecka M; Krawczuk-Rybak M; Karpińska-Derda I; Niedźwiecki M; Musioł K; Ćwiklińska M; Drabko K; Mycko K; Ociepa T; Pawelec K; Januszkiewicz-Lewandowska D; Ussowicz M; Rybka B; Ryczan-Krawczyk R; Kołtan A; Karolczyk G; Zaucha-Prażmo A; Badowska W; Kałwak K
Adv Clin Exp Med; 2018 Jan; 27(1):91-98. PubMed ID: 29521048
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
20. Reconsideration of BCR-ABL protein flow cytometric immunobead assay: how potent to diagnose and monitor chronic myeloid leukemia?
Kelani R; Monem F
Int J Lab Hematol; 2015 Oct; 37(5):723-8. PubMed ID: 26059167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
